Investment bank Citi has adopted a negative stance on Moderna, Inc. (MRNA). On Wednesday, analyst Geoff Meacham downgraded the biotechnology company to Sell from its previous Hold recommendation, a call detailed in a Barron's report.

The bearish call arrives on the heels of an extraordinary rally in Moderna's equity. Since the middle of August, the stock has soared approximately 222%, with the dramatic appreciation triggered by clinical trial updates for intismeran autogene, the experimental cancer treatment Moderna is co-developing with pharmaceutical giant Merck.

The therapy achieved its primary endpoints in a Phase 3 melanoma trial — meaning it met the pre-defined measures of success established before the study began — and market participants reacted enthusiastically to the announcement. Citi, however, believes investor optimism has now exceeded reasonable bounds.

While Meacham increased his price objective from $60 to $80, the new target still represents roughly 61% below Moderna's most recent closing price of $203.46. Following the downgrade, Moderna shares fell 5.7% to $191.96 during Wednesday's premarket session.

Key Factors Behind Citi's Bearish Stance

Citi's primary concern centers on valuation metrics. Moderna's market capitalization has expanded to approximately $80 billion, approaching the valuation of the established biotechnology company Regeneron. Fundamental performance metrics, however, tell a different story.

Wall Street consensus projections anticipate Moderna generating approximately $5.8 billion in revenue alongside $1.1 billion in net income by 2030. Regeneron's outlook is substantially different, with expectations for $22.7 billion in revenue and $8 billion in net income during the same timeframe. According to Citi, this disparity indicates that investors are embedding significant pipeline success that remains unproven.

Even assuming a 100% probability of success for intismeran across all major cancer indications, Citi estimates the treatment would justify only about $100 per share. Reaching the $200 level would necessitate approximately $13 billion in annual oncology revenue — nearly a seven-fold increase over the bank's current projections. Meacham characterized such revenue expectations as implausible.

Critical Trial Details Still Awaited

Citi acknowledged the encouraging topline outcomes from the INTerpath-001 clinical trial, which successfully achieved both its recurrence-free survival endpoint — tracking how long patients remain free of the cancer returning — and its distant metastasis-free survival endpoint, which measures the time before the disease spreads to distant organs. Detailed numerical data, however, remains undisclosed.

Critical information — including hazard ratios, safety profiles, and manufacturing scalability — has yet to be revealed. Meacham indicated that a hazard ratio near 0.72 would represent clinically meaningful results, while a figure of 0.65 or below would constitute a significant achievement. As a statistical measure, a hazard ratio below 1 indicates a lower risk of the event being studied relative to a control group, so lower figures point to a stronger treatment effect.

As a reference point, earlier Phase 2 trial data demonstrated a five-year hazard ratio of 0.51 — a benchmark that establishes elevated expectations for the forthcoming Phase 3 data.

Melanoma demonstrates particularly strong responses to immunotherapy relative to other malignancies. Meacham warned that positive melanoma results do not necessarily translate into success in kidney, lung, or bladder cancers, which present distinct biological characteristics and competitive landscapes.

The next significant data presentation is anticipated at the European Society for Medical Oncology conference, one of the field's largest annual forums for cancer research, scheduled for late October. Investors will be watching whether the detailed figures presented there — particularly the hazard ratio — address the safety and scalability questions Citi says remain open.

Wall Street Sentiment Remains Divided

Analyst sentiment on Moderna remains divided across Wall Street. Among the 20 analysts tracking the stock, six maintain Buy ratings, the majority hold neutral positions, and a small number recommend selling.

The consensus price target among Wall Street analysts stands at $110.44, a level that implies potential downside of approximately 45% from present trading levels.

Source: Blockonom